Reliance's Strand Life Sciences Secures Indian Patent

Reliance Industries' subsidiary Strand Life Sciences secured an Indian patent on July 7, 2026, for an AI-enabled blood test that detects early-stage cancer using cell-free DNA analysis. The platform combines genome sequencing with machine learning to identify cancer and its tissue of origin from a single blood draw, aiming to make precision screening more accessible in India, which faces over 1.5 million new cancer cases annually.

Reliance Industries ' subsidiary Strand Life Sciences was granted an Indian patent on July 7, 2026 for an AI-enabled blood test that detects early-stage cancer using cell-free DNA analysis, the company said in a press release carried by ANI. The patented platform combines high-quality genome sequencing, quality control, and machine-learning-based methylation and fragmentomic feature extraction to detect cancer and predict its tissue of origin from a single blood draw. CEO Ramesh Hariharan said the technology aims to make precision cancer screening "more accurate, scalable, and accessible" as India faces over 1.5 million new cancer cases a year. For practitioners, the patent is a concrete example of ML models built on sequencing and epigenetic features being deployed for real clinical screening, not just research.